DoW Alzheimer’s Transforming Diagnosis Award

The FY26 AZRP TrDA intends to support non-incremental, solutions-oriented research that reduces or overcomes important barriers to obtaining a diagnosis, meaningful disease monitoring and accurate prognosis. Barriers could include, but are not limited to, technologies, cost, patient access to diagnosis/prognosis technology, diagnosis management, applicability, clinical implementation, relationship to clinical outcome measures, biomarker validation, and lack of longitudinal data to inform prediction/prognosis. In addition, the FY26 AZRP TrDA encourages applications that address health disparities in Alzheimer’s Disease (AD) and Alzheimer’s Disease Related Dementias (ADRD) research. Applications that do not clearly delineate how the proposed research addresses and/or overcomes current challenges for diagnosis and/or prognosis do not meet the intent of this mechanism. Funded research should provide significant impact on the AD/ADRD field, Community, and military health. For the purposes of this funding opportunity, the following terms are defined as: • Military or military health refers to not only members of all components of the Armed Forces, but Veterans, their Families and other DOW beneficiaries. • Community encompasses the network of individuals living with an AD/ADRD diagnosis, their care partner(s), families, advocates, and/or other close connections. The CDMRP refers to these individuals as consumers.